
ALLO Stock Forecast & Price Target
ALLO Analyst Ratings
Bulls say
Allogene Therapeutics Inc is positioned favorably due to its innovative allogeneic T-cell therapies, which demonstrate enhanced efficacy in patients with low disease burden, achieving complete response (CR) rates of 100% and 82% in specific scenarios. The anticipated regulatory developments, including a regimen selection expected in mid-2025, coupled with the promising safety profile of their lead product cema-cel, suggests potential for effective treatment options in oncological applications. Additionally, the company's collaborative revenue streams bolster their resources for ongoing research and development, underscoring a robust foundation for future growth in the competitive biotech landscape.
Bears say
Allogene Therapeutics reported a net loss of $60 million, translating to a loss of $0.28 per share, indicating significant financial strain as the company continues to operate in a non-revenue generating status. The firm faces speculative risks due to the unpredictability of future revenues and expenses, alongside potential delays in approvals or negative trial results, which could diminish investor confidence and adversely affect share price. Additionally, competitive pressures from similar products in the market could jeopardize Allogene Therapeutics' market share, further complicating its financial outlook.
This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ALLO Analyst Forecast & Price Prediction
Start investing in ALLO
Order type
Buy in
Order amount
Est. shares
0 shares